Showing results (11-20 of 25) with videos related to
Sort By:
Pageof 3
Nature|December 16, 2021
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancerYelena Y Janjigian, Akihito Kawazoe, Patricio Yañez, et al.Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|September 1, 2021
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trialCharles S Fuchs, Mustafa Özgüroğlu, Yung-Jue Bang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2025
Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 StudyKohei Shitara, Sun Young Rha, Lucjan Wyrwicz, et al.JAMA Oncology|December 21, 2018
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 StudyManish A Shah, Takashi Kojima, Daniel Hochhauser, et al.Lancet (London, England)|October 23, 2023
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trialYelena Y Janjigian, Akihito Kawazoe, Yuxian Bai, et al.Future Oncology (London, England)|July 19, 2022
T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancerManish A Shah, Takashi Kojima, Daniel Hochhauser, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2022
Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 StudyKeun-Wook Lee, Eric Van Cutsem, Yung-Jue Bang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2021
Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10Zev A Wainberg, Charles S Fuchs, Josep Tabernero, et al.JAMA Oncology|April 1, 2021
Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical TrialsJoseph Chao, Charles S Fuchs, Kohei Shitara, et al.Lancet (London, England)|August 29, 2021
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 studyJong-Mu Sun, Lin Shen, Manish A Shah, et al.Pageof 3